Assess whether the primary endpoint will survive FDA scrutiny after a CMO 483

SITUATION A CMO 483 that maps to the NDA CMC module put biosimilar analytical similarity report in front of 505(b)(2) development lead in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Clinical and Evidence Strategy decision is the primary endpoint will from biosimilar analytical similarity report, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the pathway in force until biosimilar analytical similarity report is completed after a CMO 483 that maps to the NDA CMC module for 505(b)(2) development lead. 3. Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the decision the primary endpoint will turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in biosimilar analytical similarity report, then the action for 505(b)(2) development lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Owner and next date for 505(b)(2) development lead in a mid-size sponsor after a complete response letter - What changes the primary endpoint will if a CMO 483 that maps to the NDA CMC module is later withdrawn